The global Drugs Based on CAR T-cell market size is predicted to grow from US$ 6439 million in 2025 to US$ 32570 million in 2031; it is expected to grow at a CAGR of 31.0% from 2025 to 2031.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer
The CAR T-cell therapy drug gel market is driven by the revolutionary approach of CAR T-cell therapy in cancer treatment and the demand for targeted and personalized therapies. CAR T-cell therapy involves genetically modifying a patient"s own T cells to target and destroy cancer cells. The rise in cancer prevalence and the need for innovative treatments contribute to market growth as healthcare providers seek effective and tailored solutions for patients with difficult-to-treat cancers. Moreover, advancements in gel-based drug delivery systems have improved the precision and safety of CAR T-cell therapy administration. However, the market also faces challenges, including complex manufacturing processes and potential side effects associated with immune response. Additionally, addressing the high cost of CAR T-cell therapies and ensuring scalability and accessibility for broader patient populations can pose obstacles for manufacturers and healthcare systems. To succeed, companies must focus on advancing research and development, collaborating with oncologists to optimize therapy protocols, and addressing the challenges to meet the increasing demand for breakthrough cancer treatments.
The 鈥淒rugs Based on CAR T-cell Industry Forecast鈥� looks at past sales and reviews total world Drugs Based on CAR T-cell sales in 2024, providing a comprehensive analysis by region and market sector of projected Drugs Based on CAR T-cell sales for 2025 through 2031. With Drugs Based on CAR T-cell sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs Based on CAR T-cell industry.
This Insight Report provides a comprehensive analysis of the global Drugs Based on CAR T-cell landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drugs Based on CAR T-cell portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Drugs Based on CAR T-cell market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs Based on CAR T-cell and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs Based on CAR T-cell.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs Based on CAR T-cell market by product type, application, key players and key regions and countries.
Segmentation by Type:
CD19-targeted
BCMA-targeted
Segmentation by Application:
Lymphoma
Multiple Myeloma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Drugs Based on CAR T-cell 麻豆原创 Size (2020-2031)
2.1.2 Drugs Based on CAR T-cell 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Drugs Based on CAR T-cell by Country/Region (2020, 2024 & 2031)
2.2 Drugs Based on CAR T-cell Segment by Type
2.2.1 CD19-targeted
2.2.2 BCMA-targeted
2.3 Drugs Based on CAR T-cell 麻豆原创 Size by Type
2.3.1 Drugs Based on CAR T-cell 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Drugs Based on CAR T-cell 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Drugs Based on CAR T-cell Segment by Application
2.4.1 Lymphoma
2.4.2 Multiple Myeloma
2.5 Drugs Based on CAR T-cell 麻豆原创 Size by Application
2.5.1 Drugs Based on CAR T-cell 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Drugs Based on CAR T-cell 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Drugs Based on CAR T-cell 麻豆原创 Size by Player
3.1 Drugs Based on CAR T-cell 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Drugs Based on CAR T-cell Revenue by Player (2020-2025)
3.1.2 Global Drugs Based on CAR T-cell Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Drugs Based on CAR T-cell Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drugs Based on CAR T-cell by Region
4.1 Drugs Based on CAR T-cell 麻豆原创 Size by Region (2020-2025)
4.2 Global Drugs Based on CAR T-cell Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drugs Based on CAR T-cell 麻豆原创 Size Growth (2020-2025)
4.4 APAC Drugs Based on CAR T-cell 麻豆原创 Size Growth (2020-2025)
4.5 Europe Drugs Based on CAR T-cell 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Drugs Based on CAR T-cell 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Drugs Based on CAR T-cell 麻豆原创 Size by Country (2020-2025)
5.2 Americas Drugs Based on CAR T-cell 麻豆原创 Size by Type (2020-2025)
5.3 Americas Drugs Based on CAR T-cell 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs Based on CAR T-cell 麻豆原创 Size by Region (2020-2025)
6.2 APAC Drugs Based on CAR T-cell 麻豆原创 Size by Type (2020-2025)
6.3 APAC Drugs Based on CAR T-cell 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drugs Based on CAR T-cell 麻豆原创 Size by Country (2020-2025)
7.2 Europe Drugs Based on CAR T-cell 麻豆原创 Size by Type (2020-2025)
7.3 Europe Drugs Based on CAR T-cell 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drugs Based on CAR T-cell by Region (2020-2025)
8.2 Middle East & Africa Drugs Based on CAR T-cell 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Drugs Based on CAR T-cell 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Drugs Based on CAR T-cell 麻豆原创 Forecast
10.1 Global Drugs Based on CAR T-cell Forecast by Region (2026-2031)
10.1.1 Global Drugs Based on CAR T-cell Forecast by Region (2026-2031)
10.1.2 Americas Drugs Based on CAR T-cell Forecast
10.1.3 APAC Drugs Based on CAR T-cell Forecast
10.1.4 Europe Drugs Based on CAR T-cell Forecast
10.1.5 Middle East & Africa Drugs Based on CAR T-cell Forecast
10.2 Americas Drugs Based on CAR T-cell Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Drugs Based on CAR T-cell Forecast
10.2.2 Canada 麻豆原创 Drugs Based on CAR T-cell Forecast
10.2.3 Mexico 麻豆原创 Drugs Based on CAR T-cell Forecast
10.2.4 Brazil 麻豆原创 Drugs Based on CAR T-cell Forecast
10.3 APAC Drugs Based on CAR T-cell Forecast by Region (2026-2031)
10.3.1 China Drugs Based on CAR T-cell 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Drugs Based on CAR T-cell Forecast
10.3.3 Korea 麻豆原创 Drugs Based on CAR T-cell Forecast
10.3.4 Southeast Asia 麻豆原创 Drugs Based on CAR T-cell Forecast
10.3.5 India 麻豆原创 Drugs Based on CAR T-cell Forecast
10.3.6 Australia 麻豆原创 Drugs Based on CAR T-cell Forecast
10.4 Europe Drugs Based on CAR T-cell Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Drugs Based on CAR T-cell Forecast
10.4.2 France 麻豆原创 Drugs Based on CAR T-cell Forecast
10.4.3 UK 麻豆原创 Drugs Based on CAR T-cell Forecast
10.4.4 Italy 麻豆原创 Drugs Based on CAR T-cell Forecast
10.4.5 Russia 麻豆原创 Drugs Based on CAR T-cell Forecast
10.5 Middle East & Africa Drugs Based on CAR T-cell Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Drugs Based on CAR T-cell Forecast
10.5.2 South Africa 麻豆原创 Drugs Based on CAR T-cell Forecast
10.5.3 Israel 麻豆原创 Drugs Based on CAR T-cell Forecast
10.5.4 Turkey 麻豆原创 Drugs Based on CAR T-cell Forecast
10.6 Global Drugs Based on CAR T-cell Forecast by Type (2026-2031)
10.7 Global Drugs Based on CAR T-cell Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Drugs Based on CAR T-cell Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Drugs Based on CAR T-cell Product Offered
11.1.3 Novartis Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Drugs Based on CAR T-cell Product Offered
11.2.3 Gilead Sciences Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb Drugs Based on CAR T-cell Product Offered
11.3.3 Bristol-Myers Squibb Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bristol-Myers Squibb Main Business Overview
11.3.5 Bristol-Myers Squibb Latest Developments
11.4 J & J
11.4.1 J & J Company Information
11.4.2 J & J Drugs Based on CAR T-cell Product Offered
11.4.3 J & J Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 J & J Main Business Overview
11.4.5 J & J Latest Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Information
11.5.2 JW Therapeutics Drugs Based on CAR T-cell Product Offered
11.5.3 JW Therapeutics Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 JW Therapeutics Main Business Overview
11.5.5 JW Therapeutics Latest Developments
11.6 FOSUNKite
11.6.1 FOSUNKite Company Information
11.6.2 FOSUNKite Drugs Based on CAR T-cell Product Offered
11.6.3 FOSUNKite Drugs Based on CAR T-cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 FOSUNKite Main Business Overview
11.6.5 FOSUNKite Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
